Quanterix Corporation (QTRX), a leader in innovative biomarker analysis, announced an increase in its preliminary revenue figures for the fourth quarter on Tuesday.
During the final quarter ending December 31, 2024, the company achieved revenue of approximately $34.9 million, marking an 11% increase from the corresponding period in the previous year.
Revenue generated from the consumables segment remained stable at $17.4 million.
For the entire fiscal year, Quanterix reported a revenue of about $137.2 million, which signifies a 12% growth compared to the previous year.
The revenue from the consumables segment for the full year reached roughly $69.3 million, reflecting an 8% increase from the last year.
In pre-market trading on the Nasdaq, QTRX shares experienced a rise, trading at $9.99, up 9.66%.
